Dabigatran Etexilate ( DrugBank: Dabigatran etexilate, Dabigatran )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 51 | Scleroderma | 1 |
| 75 | Cushing disease | 1 |
51. Scleroderma
Clinical trials : 525 / Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02426229 (ClinicalTrials.gov) | February 2016 | 4/3/2015 | Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma | Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma | Scleroderma;Interstitial Lung Disease | Drug: dabigatran etexilate | Medical University of South Carolina | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | 18 Years | 70 Years | All | 15 | Phase 1 | United States |
75. Cushing disease
Clinical trials : 205 / Drugs : 176 - (DrugBank : 45) / Drug target genes : 61 - Drug target pathways : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05347979 (ClinicalTrials.gov) | May 25, 2022 | 18/4/2022 | Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants | An Open-Label, Drug-Drug Interaction Study Designed to Evaluate the Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Subjects | Cushing Syndrome;Neoplasms | Drug: Dabigatran Etexilate;Drug: Relacorilant | Corcept Therapeutics | NULL | Completed | 18 Years | 55 Years | All | 30 | Phase 1 | United States |